Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

over existing therapeutic approaches for Crohn's disease by potentially offering reduced side effects and convenient oral dosing to patients. Traficet-EN is being developed under a strategic alliance with GlaxoSmithKline's Center of Excellence for External Drug Discovery (CEEDD).

About Crohn's Disease

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. It is estimated that the disease affects over 500,000 patients in Europe and North America. Patients suffer periods of flare-ups characterized by intense symptoms, interspersed with periods of relative remission where symptoms decrease or disappear. As Crohn's disease is a chronic condition, patients continue on a given therapeutic regimen from the time of diagnosis over the course of a lifetime, layering additional therapies as flare-ups recur or persist in an effort to reduce symptoms. When medications can no longer control symptoms, patients have few options beyond surgery.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, is in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX025, also a CCR9 antagonist, is in a Phase I clinical trial
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014   Mast Therapeutics, ... company, announced today that Santosh Vetticaden, Chief Medical ... the Company, for personal reasons, in mid-September.  ... Officer of Aires Pharmaceuticals, which Mast acquired earlier ... as the Company,s interim Chief Medical Officer.  Dr. ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Peptide Cancer Therapeutics Market & Pipeline ... The conventional methods developed to prevent and eradicate ... cancer treatment. These methods are confined to low specificity, ... the researchers to look for a better solution. It ...
(Date:8/29/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... District of New Jersey has ... Sandoz, Inc. regarding United Therapeutics, Remodulin ® product.  In ... U.S. Patent No. 6,765,117 is both valid and enforceable ... generic product until the expiration of that patent in ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... RIDGEFIELD, CT, Sept. 21, 2011 Boehringer Ingelheim,s investigational ... trend in reducing lung function decline in patients with ... trial results published today online in the New ... is a progressive and severely debilitating lung disease with ...
... new electronic medication system, the Artemis system, is now in ... which adds a new level of safety when it ... an emergency situation. The Artemis system ...  Dr. James Broselow, inventor of ,The Broselow Tape, and Dr. ...
Cached Medicine Technology:New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis 2New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis 3New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis 4New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis 5New Electronic Child Medication Safety System Launches at Rocky Mountain Hospital for Children at Presbyterian/St. Luke's Medical Center 2New Electronic Child Medication Safety System Launches at Rocky Mountain Hospital for Children at Presbyterian/St. Luke's Medical Center 3
(Date:9/1/2014)... September 02, 2014 PAINWeek, the National ... the American Pain Society (APS) will return to the ... expertise in pain management to the agenda. This activity ... no fee to attend this program. , On Thursday, ... activity that complies with the FDA’s Risk Evaluation and ...
(Date:9/1/2014)... State University study of deadly force were more likely ... when it came time to shoot, participants were biased ... the trigger against them than against armed white or ... Journal of Experimental Criminology , grow out of dozens ... ethnic and racial minorities shot by police. The studies ...
(Date:9/1/2014)... iFitDress.com, a professional company of women’s dresses and ... modest evening dresses . In addition, the company ... evening gowns. All customers can enjoy a big discount, ... , iFitDress.com is one of the leading suppliers in ... are striving to create more trendy items. The company's ...
(Date:9/1/2014)... AZ (PRWEB) September 01, 2014 Building ... conference, the American Sleep and Breathing Academy ... conference: A Conference for Healthcare Professionals. The event will ... Arizona on April 10th and 11th. This years’ event ... delivered by the ASBA. , In recent years, ...
(Date:9/1/2014)... was associated with mental health and substance use ... protect teens from the consequences of cyberbullying and ... Author: Frank J. Elgar, Ph.D., of McGill University, ... in 5 adolescents has experienced recent online bullying ... risk of mental health problems in teens as ...
Breaking Medicine News(10 mins):Health News:American Pain Society Returns with REMS Training at PAINWeek 2014 in Las Vegas 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 2Health News:WSU 'deadly force' lab finds racial disparities in shootings 3Health News:iFitDress.com: New Modest Evening Wear Selection Now Unveiled Online 2Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 2Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 3Health News:Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference 4Health News:Family dinners good for teens' mental health, could protect from cyberbullying 2Health News:Family dinners good for teens' mental health, could protect from cyberbullying 3
... Twelve senior U.S. editors and producers traveled to ... of Africa,s most fascinating countries. A highlight of the ... development, food security, and HIV/AIDS with Ugandan President Yoweri ... at noon , three of the Gatekeepers will discuss ...
... number of childhood deaths across the country have been linked ... this serious and sometimes deadly disease with an annual flu ... a relatively high level across the country, now is the ... do so. It takes about two weeks for the body ...
... Sleep Awareness Week -- March 1-8 -- ... importance of a good night,s sleep by raising ... sleep bruxism. (Logo: http://www.newscom.com/cgi-bin/prnh/20070809/AQTH133LOGO )Sleep bruxism is ... associated with sleep deprivation, stress or misalignment of ...
... showing at the 2009,South Beach Food and Wine Festival, ... 300 stores in South Florida since the brand launched ... include: CVS on Lincoln Road,Miami Beach; Walgreens, Miami Beach; ... Thumb, Penn Dutch, Quick Stop, Shell Gas Stations, and,Chevron. ...
... in Health Incentive ProgramsLYNDHURST, N.J., Feb. 24 ... to the health care industry, announced today that ... serve the industry in the area of incentive ... seasoned health and productivity professionals have long been ...
... to help health care providers,prepare patients for a colonoscopy ... makes TriLyte(R) (PEG-3350, sodium chloride, sodium bicarbonate,and potassium chloride ... is indicated for bowel cleansing prior to a,colonoscopy. , ... patients who are preparing for a,colonoscopy by explaining the ...
Cached Medicine News:Health News:U.S. Media Report From Uganda: Wilson Center Panel Discusses Health, Environment, and Security in Africa 2Health News:Recently Reported Childhood Deaths from Influenza Are a Stark Reminder to Vaccinate Now 2Health News:GIVE IT A REST: Delta Dental of Illinois Encourages Routine Dental Exams to Help Detect Nighttime Teeth Grinding 2Health News:Next Generation Waters Successfully Reaches Over 300 Stores! 2Health News:IncentOne Launches Consulting Practice 2Health News:Free Video for Health Care Providers and Patients Who are Preparing for a Colonoscopy Is Now Available at www.TriLyte.com 2
Double-ended. 5 mm x 7 mm tips. Designated most popular model or size....
Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end....
Double-ended. Semi sharp. Curved 3 mm tips. Angled right and left....
Double-ended. Designated most popular model or size....
Medicine Products: